Navigation Links
Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc.

SEATTLE, Dec. 18 /PRNewswire-FirstCall/ -- Pacific Biometrics, Inc. (OTC Bulletin Board: PBME) ("PBI" or "the Company"), a leading provider of specialized central laboratory and contract research services, today announced that its stockholders approved all three proposals that were voted upon at the Company's Annual Meeting on December 14, 2009.

A majority of stockholders voted to approve a change in the Company's name to "Pacific Biomarkers, Inc." The corporate name change will become effective upon filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of Delaware. The name change must also be submitted to the Financial Industry Regulatory Authority (FINRA) for review. In connection with this required notification, FINRA will assign a new ticker symbol for the Company's common stock.

"Since PBI's creation, we have provided high-quality esoteric assay services for clinical drug and diagnostic product development," stated Ron Helm, the Company's Chief Executive Officer. "Many of these assay services are encompassed by the term 'biomarker', which refers to any biological parameter that can be measured in patient samples and that provides specific information about the effects of a particular drug. Over the past five years, we have seen an accelerating trend towards the use of biomarkers in all phases of drug development, and many expect that this will lead to true personalized medicine. Therefore, our business strategy to focus on this type of testing is even more relevant today than it was when the Company was founded."

"To capture an even greater share of this rapidly growing market, we have aggressively expanded our service offering to include custom assay services for our pharmaceutical and biotechnology clients," continued Helm. "In addition to our traditional biomarker services, we also provide assay development services for novel biomarkers, as well as custom assay services for immunogenicity testing, cell based assay testing and multiplex testing. We anticipate that our enhanced clinical biomarker services will help diversify our client base, because these services apply to therapeutic areas beyond our traditional specialty areas, and there is also a growing emphasis on biologic drugs."

"For these reasons, we believe that the name 'Pacific Biomarkers, Inc.' more accurately reflects both our current and historical strengths. The term 'biomarker' is now much more widely known and is broadly understood to have a key role in drug development. Therefore, the new name accurately positions us as a specialty laboratory provider for contemporary drug development services," concluded Helm.

Also at the Annual Meeting, stockholders re-elected the seven members of the Company's Board of Directors:

                                    Ronald R. Helm
                                    Mario R. Ehlers
                                     Paul G. Kanan
                                 Richard W. Palfreyman
                                   Curtis J. Scheel
                                   Stanley L. Schloz
                                   Kenneth R. Waters

The third proposal on the agenda at the Annual Meeting, which was also approved by the stockholders, ratified the Audit Committee's selection of PMB Helin Donovan, LLP as the Company's independent auditors for the 2010 fiscal year. PMB Helin Donovan, LLP has audited the Company's financial statements since September 5, 2007.

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company's biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).

SOURCE Pacific Biometrics, Inc.

SOURCE Pacific Biometrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Announcing IOF Regionals 1st Asia-Pacific osteoporosis meeting
2. Pacific Biometrics Inc. Reports First Quarter Operating Results
3. Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers
4. Global warming may spur increased growth in Pacific Northwest forests
5. Pacific Biometrics Completes $4 Million Debt Financing
6. New project to forecast toxic algal blooms on Pacific Northwest beaches
7. AAAS Pacific division scientific conference to meet in San Francisco Aug. 14 - 19
8. Pacific Northwest forests could store more carbon, help address greenhouse issues
9. Scientists urge world leaders to respond cooperatively to Pacific Ocean threats
10. Invasives threaten salmon in Pacific Northwest
11. Smithsonian puts tropical eastern Pacific shore fishes online
Post Your Comments:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: